CTIS2022-502087-21-00进行中（未招募）1 期
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) - THE630-21-101
Theseus Pharmaceuticals Inc.0 个研究点目标入组 160 人开始时间: 2023年2月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
2022-502087-21-00 Results v1
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female patient = 18 years of age., Female patients of childbearing potential must agree to abstain from heterosexual intercourse or use a highly effective form of contraception with their sexual partners during the dosing period and for a period of at least 7 months after the end of treatment. Male patients with partners of childbearing potential must agree that they will abstain from heterosexual intercourse or use condoms and their partners will use highly effective contraceptive methods during the dosing period until at least 4 months after the last dose of study drug., All toxicities from prior therapy have resolved to = grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or have resolved to baseline, at the time of first dose of study drug. Note: treatment-related grade >1 alopecia, treatment related grade 2 peripheral neuropathy, and treatment-related grade 2 hypothyroidism on a stable dose of thyroid hormone replacement therapy are allowed if deemed irreversible., Patient or legal guardian, if permitted by local regulatory authorities, signed and dated informed consent indicating that the patient has been informed of all pertinent aspects of the study. Note: Patients are not eligible if they are, for reasons other than the age of legal competence to give informed consent, incapable of giving informed consent according to the law of the country concerned., Willingness and ability to comply with scheduled visits and study procedures and do not have any contraindications to any of the study procedures., For Dose Escalation Phase Cohorts (Phase 1): a. Have histologically- or cytologically-confirmed unresectable or metastatic GIST. b. Have progressed on or are intolerant to imatinib therapy and have also received at least 1 of the following: sunitinib, regorafenib, ripretinib, or avapritinib., For Expansion Phase Cohorts (Phase 2): a. Cohort 1: i. Have histologically- or cytologically confirmed unresectable or metastatic GIST. ii. Have progressed on or are intolerant to imatinib, sunitinib, regorafenib and ripretinib. b. Cohort 2: i. Have histologically- or cytologically confirmed unresectable or metastatic GIST. ii. Have progressed on or are intolerant to imatinib and sunitinib. Patients in this cohort are allowed to have received up to 1 additional line of therapy in the advanced/metastatic setting. c. Cohort 3: i. Have histologically- or cytologically confirmed unresectable or metastatic GIST. ii. Have progressed on or are intolerant to imatinib (including in the adjuvant setting). iii. Have not received additional systemic therapy for advanced GIST., Have at least 1 measurable lesion as defined by modified RECIST 1.1, Have archival or new tumor biopsy tissue available to submit for mutational testing. A tumor sample obtained after most recent prior systemic anticancer therapy is preferred. Patients without appropriate archival tissue available may be discussed with the study medical monitor and approved for enrollment on a case-by-case basis., Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, Adequate renal and hepatic function as defined by the following criteria: a. Total serum bilirubin =1.5 × upper limit of normal (ULN) (<3.0 x ULN for patients with Gilbert syndrome), b. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =3 × ULN (or =5 × ULN if liver function abnormalities are due to underlying malignancy), an
排除标准
- •Received systemic anticancer therapy (including cytotoxic chemotherapy, investigational agent, antineoplastic monoclonal antibodies, or immunotherapy) less than 5 half-lives or 14 days (whichever is shorter) prior to the first dose of study drug OR have received medications that are potent inhibitors of the BCRP (refer to Appendix 5 for a list of these medications) 7 days prior to the first dose of study drug., Any active bleeding excluding hemorrhoidal or gum bleeding., For patients with a known human immunodeficiency virus (HIV) infection, have CD4+ T-cell counts <350 cells/uL or history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months. Patients with HIV infection should be on established antiretroviral therapy (ART) for at least 4 weeks and have an HIV viral load less than 400 copies/mL prior to enrollment., Has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, as evidenced by detectable viral load (HBV-DNA or HCV-RNA, respectively). Risk of HBV reactivation should be considered in all patients and the need for anti-HBV prophylaxis should be carefully assessed. Patients with chronic HBV infection with history of active disease who meet the criteria for anti HBV therapy should be on a suppressive antiviral therapy to be eligible for enrollment. Patients who are HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Patients on concurrent HCV treatment at the time of enrollment are allowed if HCV RNA negative., Pregnant or breastfeeding., Malabsorption syndrome or other illness that could affect oral absorption., Patients with prior or concurrent malignancies other than GIST are allowed, except in the case where, in the opinion of the Investigator, the natural history or treatment of the other malignancy has the potential to interfere with the safety or efficacy assessment of the study drug., Have any condition or illness that, in the opinion of the Investigator, might compromise patient safety or interfere with the evaluation of the safety of the drug., Patients known to be both KIT and PDGFRA wild-type., Received radiotherapy within 14 days prior to the first dose of study drug., Major surgical procedure within 28 days of the first dose of study drug. Minor surgical procedures such as central venous catheter placement or minimally invasive biopsy are allowed., Have known untreated or active central nervous system metastases., 12-lead electrocardiogram (ECG) demonstrating QT interval corrected by Fridericia's formula (QTcF) > 470 msec at screening, or history of long QTc syndrome., Have significant, uncontrolled, or active cardiovascular disease, including, but not restricted to: a. Myocardial infarction (MI) within 6 months prior to the first dose of study drug b. Unstable angina within 6 months prior to first dose of study drug c. Symptomatic congestive heart failure (New York Heart Association classes II-IV) within 6 months prior to first dose of study drug d. Clinically significant, uncontrolled atrial arrhythmia (as determined by the Investigator) e. Any history of ventricular arrhythmia f. Cerebrovascular accident or transient ischemic attack within 6 months prior to first dose of study drug g. Uncontrolled hypertension at study entry. Patients with hypertension should be under treatment on study entry to control blood pressure., Have an active uncontrolled infection, including, but not limited to, the require
研究者
相似试验
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660:cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-ITASTEX PHARMACEUTICALS230
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660: cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-GBAstex Pharmaceuticals, Inc.230
招募中
2 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.2024-516679-33-00Taiho Oncology Inc.16
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: cohort 1:Recurrent/metastatic head and neck squamous cell carcinomacohort 2:Relapsed or refractory diffuse large B-cell lymphomacohort 3:Progressive, refractory or relapsed peripheral T-cell lymphomacohort 4:Relapsed or refractory cutaneous T-cell lymphomacohort 5: Other tumor types that may have sensitivity to ASTX660: cohort 6: Cervical carcinoma not responsive or relapsed after standard therapyMedDRA version: 21.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10008229Term: Cervical cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-005039-34-HUAstex Pharmaceuticals, Inc.230
进行中（未招募）
1 期
Study of the safety, activity, and effect on the body of ASTX660 in people with advanced cancers.EUCTR2016-005039-34-FRAstex Pharmaceuticals, Inc.200